Continuing Medical Education Post-Test

Size: px
Start display at page:

Download "Continuing Medical Education Post-Test"

Transcription

1 Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on the answer sheet on page 89. To receive Category I credit, complete the post-test and record your responses on the answer sheet. Mail in the return envelope no later than February 1, A passing grade of 80% is needed to receive credit. A certificate will be sent to you upon your successful completion of this post-test. Management of non-st-segment Elevation Acute Coronary Syndrome (NSTE-ACS) in the ED: State-of-the-Art Anti-platelet Management 1. Which of the following anti-platelet drugs is indicated in the emergency department management of high risk NSTE-ACS? a) Clopidogrel b) Glycoprotein IIb/IIIa inhibitors c) Aspirin 2. Based on the ARMYDA-2 trial, what are the effects of increasing the loading dose of clopidogrel to 600 mg prior to PCI? a) Increase in bleeding complications b) Reduction in death, MI, and target vessel revascularization c) Increase in CABG related bleeding d) Reduction in bleeding complications. 3. According to the ISAR REACT-2 trial, which group of high risk NSTE-ACS patients received the most benefit from the addition of a GP IIb/IIIa inhibitor during PCI? a) Troponin negative patients b) Troponin positive patients c) ECG ST segment depression patients Non-ST-segment Elevation Acute Coronary Syndrome: Optimal Anti-Coagulant Therapy for the Emergency Department 5) For patients with NSTE ACS presenting to the ED, which of the following represent guideline-indicated therapy? a) Heparin b) Low molecular weight heparin c) Both A and B d) Neither A and B 6) Low molecular weight heparin is prepared through fractionation of the parent compound, heparin. 7) In the ESSENCE and TIMI IIB trials, enoxaparin reduced the composite end points of death, MI, or recurrent angina/need for urgent revascularization compare to heparin. 8) In the SYNERGY trial, which of the following patients experienced increased risk of bleeding? a) Elderly patients b) Patients with renal insufficency c) Patients experiencing switching between unfractionated heparin and enoxaparin 4. According to the ACUITY Timing trial results, which of the following patients received the most benefit in ischemic endpoint reduction with upstream GP IIb/IIIa inhibition? a) CABG patients b) Medical management patients c) PCI patients 81

2 CRUSADE Quality Improvement Initiative: Better Care for Patients with Unstable Angina and non- ST-segment Elevation Myocardial Infarction 9) The CRUSADE initiative includes the following types of patients: a) Only those with ST-segment elevation myocardial infarction. b) All chest pain patients admitted to the hospital c) Only chest pain patients admitted when a myocardial infarction d) Patients with a Non-ST-segment elevation myocardial infarction and ST-segment depression, as well as cardiac biomarker positivity. 10) The CRUSADE initiative has the following objectives: a) To determine compliance with AHA/ACC guidelines for the management of these patients in the acute setting and time of discharge b) To educate physicians about the AHA/ACC guidelines for NSTEMI ACS c) To provide quality improvement tools 11) The CRUSADE initiative has been used to evaluate the following subjects except: a) Disparities in care based on gender b) Direct comparison of pharmacologic agents in a prospective, randomized fashion c) Cardiac biomarker discrepancies d) Disparities in care based on race ST-segment Elevation Myocardial Infarction (STEMI): Decreasing the Time to Treatment in the ED 12) For patients presenting to the emergency department with STEMI, the ideal maximum door-to-needle time for infusion of fibrinolytic therapy is 30 minutes while the maximum door-to-balloon inflation time for percutaneous coronary intervention (PCI) is 90 minutes. 13) Myocardial muscle salvage for patients with STEMI, based on trials of fibrinolytic therapy, occurs up to the following time after symptom onset: a) 4 hours d) 16 hours b) 8 hours e) 20 hours c) 12 hours 14) Based on National Registry of Myocardial Infarction data for patients undergoing PCI for STEMI from 1994 through 1998, the advantage for mechanical intervention decreases substantially how many minutes after presentation to the ED: a) 30 minutes c) 90 minutes b) 60 minutes d) 120 minutes 15) For patients being transferred from one hospital to another hospital for PCI, what percentage of patients typically receive a door-to-balloon time of 90 minutes or less at the receiving hospital? a) 5% d) 20% b) 10% e) 30% c) 15% 16) In the D2B program instituted by the American College of Cardiology in November 2006, emergency physicians are responsible for activating the cardiac catheterization team to decrease the doorto-balloon time for patients presenting with STEMI. Novel Anti-thrombotic Therapies for Acute Coronary Syndrome: Direct Thrombin Inhibitors 17) New landmark studies in patients with acute coronary syndromes have focused on which of the following in the primary outcome: a) Death b) Acute myocardial infarction c) Urgent revascularization d) Bleeding complications e) All of the above including both efficacy and safety parameters f) 1, 2, 3 as the efficacy parameters 82

3 18) Bivalirudin monotherapy was associated with reduction in ischemic endpoints 19) Use of glycoprotein IIb/IIIa receptor antagonists was associated with an increase in bleeding endpoints, whether it was used with heparin or bivalirudin 20) Bivalirudin monotherapy (without concurrent glycoprotein 2b/3a receptor antagonists) was associated with reduction in bleeding endpoints, as well as an improvement in net clinical benefit. Management of ST-segment Elevation Myocardial Infarction in the ED: State-of-the-Art Anti-platelet and Anti-thrombotic Therapy 21) Which of the following anti-platelet drugs is NOT presently recommended by the ACC/ AHA Guidelines for the emergency department management of STEMI? a) Clopidogrel b) Glycoprotein IIb/IIIa inhibitors c) Aspirin d) None of the above 22) Based on the CLARITY trial, what are the effects of adding clopidogrel 300 mg to aspirin and fibrinolytic therapy in the ED treatment of STEMI? a) Increase in intracranial hemorrhage b) Reduction in death, MI, and occluded artery at angiogram c) Increase in PCI-related mortality d) Reduction in bleeding complications. 23) According to the ASSENT-4 Trial, the routine utilization of fibrinolytic therapy prior to immediate primary PCI results in: a) Increased intracerebral complications b) Increased mortality c) Worse ischemic outcomes 24) According to the TITAN TIMI-34 trial, utilization of GPI s for facilitated primary PCI results in: a) Increase angiographic reperfusion at angiogram b) Increased tissue perfusion at angiogram c) No significant increase in bleeding Acute Decompensated Heart Failure: Novel Approaches to Classification and treatment 25) When used for ADHF, IV nitroglycerin provides the following: a) Reduces mortality b) Improves symptoms of congestion c) Neither d) Both 26) All patients with ADHF should receive IV vasoldilators and IV diuretics: 27) Most patients with acute flash pulmonary edema have: a) Diastolic dysfuction b) Systolic dysfuction c) Severe hypertension d) Hypotension e) a and c f) b and d 28) The majority of ADHF patients require admission to the ICU: Lactate - A Marker for Sepsis and Trauma 29) Lactate is a product of anaerobic metabolism. 30) Seizures can cause a transient elevation in serum lactate. 83

4 31) Stable or increasing serum lactate levels are associated with improved mortality in septic patients. 32) Lactate is cleared by the liver, kidney, brain, and red blood cells. Point-of-Care Testing for Cardiac Biomarkers in the ED: Blueprint for Implementation 33) Factors which have increased the growth of pointof-care (POC) testing for cardiac biomarkers in the United States include all of the following except: a) Large volume of patients presenting to emergency departments each year causing overcrowding. b) Guidelines for non-st-segment elevation acute coronary syndrome published in c) The low cost of the POC test compared to the central laboratory assay. d) Decreased complexity of performing the POC test compared to using an assay performed on a central laboratory analyzer. 34) Cardiac biomarkers which are commonly used for POC testing in the emergency department include all of the following except: a) Myosin heavy chain b) Myoglobin c) CK-MB d) Troponin e) BNP (brain natriuretic peptide) 35) POC testing for cardiac biomarkers in the emergency department can be used for risk stratification and to identify patients with ACS for treatment with antithrombotic and anti-platelet agents 36) From the laboratory perspective, usual turn-around time (TAT) for cardiac biomarker testing includes pre-analytical time which occurs in the emergency department and the actual analysis of the specimen and reporting of the results back to the emergency physician. 37) Stakeholders for the implementation of a POC testing program in an emergency department should include: a) Laboratorians b) Clinicians c) Hospital administrators Advances in Acute Stroke Care 38) CT perfusion is designed to show areas of: a) ischemia b) infarction c) both d) neither 39) MRA and CTA are both capable of documenting proximal cerebral vessel occlusion. 40) Intra-arterial mechanical embolectomy devices have been shown to: a) Improve rate of recanalization b) Improve mortality c) Improve long-term outcomes 41) Recombinant Factor VIIa has been shown to: a) Decrease hemorrhage volume b) Improve mortality c) Improve long-term outcomes 84

5 ACEP 2006 Scientific Assembly EMCREG Symposia Continuing Medical Education Post-Test Answer Form and Evaluation After you have read the monograph, carefully record your answers by circling the appropriate letter for each question and complete the evaluation questionnaire. Mail the answer sheet to: Office of Continuing Medical Education University of Cincinnati College of Medicine PO Box Cincinnati OH CME expiration date February 1, a b c d 2. a b c d 3. a b c d 4. a b c d 5. a b c d 6. a b 7. a b 8. a b c d 9. a b c d 10. a b c d 11. a b c d 22. a b c d 23. a b c d 24. a b c d 25. a b c d 26. a b 27. a b c d e f 28. a b 29. a b 30. a b 31. a b 32. a b EVALUATION QUESTIONNAIRE On a scale of 1 to 5, with 1 being highly satisfied and 5 being highly dissatisfied, please rate this program with respect to: Highly satisfied Highly dissatisfied Overall quality of material: Content of monograph: Other similar CME programs: How well course objectives were met: What topics would be of interest to you for future CME programs? Was there commercial or promotional bias in this monograph? YES NO If YES, please explain: How long did it take for you to complete this monograph? 12. a b 13. a b c d e 14. a b c d 15. a b c d e 16. a b 17. a b c d e f 18. a b 19. a b 20. a b 21. a b c d 33. a b c d 34. a b c d e 35. a b 36. a b 37. a b c d 38. a b c d 39. a b 40. a b c 41. a b c d Name (Please print clearly): Degree: Specialty: Academic Affiliation (if applicable): Address: City: State: Zip Code: Telephone Number: ( ) 85

Continuing Medical Education Post-Test

Continuing Medical Education Post-Test Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on

More information

2010 ACLS Guidelines. Primary goals of therapy for patients

2010 ACLS Guidelines. Primary goals of therapy for patients 2010 ACLS Guidelines Part 10: Acute Coronary Syndrome Present : 內科 R1 鍾伯欣 Supervisor: F1 吳亮廷 991110 Primary goals of therapy for patients of ACS Reduce the amount of myocardial necrosis that occurs in

More information

Update on Antithrombotic Therapy in Acute Coronary Syndrome

Update on Antithrombotic Therapy in Acute Coronary Syndrome Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms

More information

An update on the management of UA / NSTEMI. Michael H. Crawford, MD

An update on the management of UA / NSTEMI. Michael H. Crawford, MD An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB

More information

Acute Coronary syndrome

Acute Coronary syndrome Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood

More information

Appendix: ACC/AHA and ESC practice guidelines

Appendix: ACC/AHA and ESC practice guidelines Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level

More information

Management of Acute Myocardial Infarction

Management of Acute Myocardial Infarction Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care

More information

ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department

ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for

More information

Acute Coronary Syndromes

Acute Coronary Syndromes Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management

More information

NEW CONCEPTS AND EMERGING TECHNOLOGIES FOR EMERGENCY PHYSICIANS

NEW CONCEPTS AND EMERGING TECHNOLOGIES FOR EMERGENCY PHYSICIANS SEPTEMBER 2007 volume 5 C O L L A B O R AT E I N V E S T I G AT E E D U C AT E Use of Direct Thrombin Inhibitors for Treating Non-ST-Segment Elevation Acute Coronary Syndromes in Special Patient Groups:

More information

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute

More information

Acute coronary syndromes

Acute coronary syndromes Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.

More information

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart

More information

Acute Coronary Syndrome

Acute Coronary Syndrome Acute Coronary Syndrome Clinical Manifestation of CAD Silent Ischemia/asymptomatic Stable Angina Acute Coronary Syndrome (Non- STEMI/UA and STEMI) Arrhythmias Heart Failure Sudden Death Pain patterns with

More information

CLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA

CLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research

More information

Acute Myocardial Infarction

Acute Myocardial Infarction Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:

More information

FastTest. You ve read the book now test yourself

FastTest. You ve read the book now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

More information

APPENDIX F: CASE REPORT FORM

APPENDIX F: CASE REPORT FORM APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more

More information

Myocardial Infarction In Dr.Yahya Kiwan

Myocardial Infarction In Dr.Yahya Kiwan Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting

More information

Current Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN

Current Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure

More information

2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY

2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY 2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA Professor and Chairman, Department of Emergency

More information

4. Which survey program does your facility use to get your program designated by the state?

4. Which survey program does your facility use to get your program designated by the state? STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI

More information

Unstable angina and NSTEMI

Unstable angina and NSTEMI Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the

More information

Acute Myocardial Infarction. Willis E. Godin D.O., FACC

Acute Myocardial Infarction. Willis E. Godin D.O., FACC Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable

More information

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4

More information

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Learning Objectives. Epidemiology of Acute Coronary Syndrome Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet

More information

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic

More information

Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013

Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013 Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville

More information

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical

More information

ST-elevation myocardial infarctions (STEMIs)

ST-elevation myocardial infarctions (STEMIs) Guidelines for Treating STEMI: Case-Based Questions As many as 25% of eligible patients presenting with STEMI do not receive any form of reperfusion therapy. The ACC/AHA guidelines highlight steps to improve

More information

Acute coronary syndrome (ACS) is an

Acute coronary syndrome (ACS) is an OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia

More information

NOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS

NOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and

More information

Antiplatelet therapy is the mainstay of pharmacological

Antiplatelet therapy is the mainstay of pharmacological Contemporary Reviews in Interventional Cardiology Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era Review of the Evidence and Practice

More information

Pharmaco-Invasive Approach for STEMI

Pharmaco-Invasive Approach for STEMI Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle  holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :

More information

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the

More information

Pathophysiology of ACS

Pathophysiology of ACS Pathophysiology of ACS ~ 2.0 MM patients admitted to CCU or telemetry annually 0.6 MM ST-segment elevation MI 1.4 MM Non-ST-segment elevation ACS NSTEMI vs STEMI VANQWISH Boden et al N Engl J Med 1998;338:1785-1792

More information

Clopidogrel Date: 15 July 2008

Clopidogrel Date: 15 July 2008 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium bivalirudin, 250mg powder for concentrate for solution for injection or infusion (Angiox ) No. (516/08) The Medicines Company UK Ltd 07 November 2008 The Scottish Medicines

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

Acute Coronary Syndrome. Emergency Department Updated Jan. 2017

Acute Coronary Syndrome. Emergency Department Updated Jan. 2017 Acute Coronary Syndrome Emergency Department Updated Jan. 2017 Goals and Objectives To reduce mortality and morbidity for people who have cardiovascular disease, with a focus on those who experience an

More information

Acute Coronary Syndrome

Acute Coronary Syndrome ACUTE CORONOARY SYNDROME, ANGINA & ACUTE MYOCARDIAL INFARCTION Administrative Consultant Service 3/17 Acute Coronary Syndrome Acute Coronary Syndrome has evolved as a useful operational term to refer to

More information

TYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016

TYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016 TYPE II MI KC ACDIS LOCAL CHAPTER March 8, 2016 TYPE 2 MI DEFINITION: Acute coronary syndrome (ACS) encompasses a continuum of myocardial ischemia and infarction, which can make the diagnostic and coding

More information

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post

More information

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main

More information

Is the role of bivalirudin established?

Is the role of bivalirudin established? Is the role of bivalirudin established? Rob Henderson Consultant Cardiologist Trent Cardiac Centre Nottingham University Hospitals Conflicts of Interest: None Declarations: Member NICE Unstable Angina

More information

A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS

A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in

More information

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs

More information

Managing Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics

Managing Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics Managing Quality of ACS Care in VHA The IDH Guideline Key Points and Metrics Robert L. Jesse, MD, PhD National Program Director for Cardiology Veterans Health Administration Washington, DC Chief, Cardiology

More information

Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial

Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.

More information

Acute coronary syndrome (ACS) is a potentially

Acute coronary syndrome (ACS) is a potentially DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.

More information

ST Elevated Myocardial Infarction- Latest AHA recommendations

ST Elevated Myocardial Infarction- Latest AHA recommendations ST Elevated Myocardial Infarction- Latest AHA recommendations Sherry Turner, DO, MPH, FACOEP Medical Director Emergency Services Wesley Medical Center The Problem 250,000 Americans each year 30% fail to

More information

Is there a real need for new agents to optimize efficacy/safety balance

Is there a real need for new agents to optimize efficacy/safety balance Anticoagulation in acute coronary syndrome Is there a real need for new agents to optimize efficacy/safety balance Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures

More information

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1. Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical

More information

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients? Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at

More information

Clinical Lessons from BMC2-PCI

Clinical Lessons from BMC2-PCI Clinical Lessons from BMC2-PCI The Blue Cross Blue Shield of Michigan Cardiovascular Consortium Hitinder Gurm, M.D. University of Michigan Overview 32 papers since inception 10 papers published this year

More information

Novel Anticoagulation Therapy in Acute Coronary Syndrome

Novel Anticoagulation Therapy in Acute Coronary Syndrome Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux

More information

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction Ramzi Khalil MD FACC Assistant Professor Allegheny Gen.Hospital AHN Speakers

More information

Non ST Elevation-ACS. Michael W. Cammarata, MD

Non ST Elevation-ACS. Michael W. Cammarata, MD Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar

More information

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM REVIEW DATE REVIEWER'S ID HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM : DISCHARGE DATE: RECORDS FROM: Hospitalization ER Please check all that may apply: Myocardial Infarction Pages 2, 3,

More information

Thrombolysis in Acute Myocardial Infarction

Thrombolysis in Acute Myocardial Infarction CHAPTER 70 Thrombolysis in Acute Myocardial Infarction J. S. Hiremath Introduction Reperfusion of the occluded coronary artery at the earliest is the most important aim of management of STEMI. Once a flow

More information

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants

More information

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total

More information

Pre Hospital and Initial Management of Acute Coronary Syndrome

Pre Hospital and Initial Management of Acute Coronary Syndrome Pre Hospital and Initial Management of Acute Coronary Syndrome Dr. Muhammad Fadil, SpJP 3rd SymCARD 2013 Classification of ACS ESC Guidelines for the management of Acute Coronary Syndrome in patients without

More information

Otamixaban for non-st-segment elevation acute coronary syndrome

Otamixaban for non-st-segment elevation acute coronary syndrome Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not

More information

Clinical Investigations

Clinical Investigations Clinical Investigations The Usage Patterns of Cardiac Bedside Markers Employing Point-of-Care Testing for Troponin in Non-ST-Segment Elevation Acute Coronary Syndrome: Results from CRUSADE Address for

More information

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet

More information

(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris

(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial

More information

QUT Digital Repository:

QUT Digital Repository: QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.

More information

Measuring Natriuretic Peptides in Acute Coronary Syndromes

Measuring Natriuretic Peptides in Acute Coronary Syndromes Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health

More information

Disclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None

Disclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines

More information

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927

More information

Downloaded from:

Downloaded from: Annemans, L; Danchin, N; Van de Werf, F; Pocock, S; Licour, M; Medina, J; Bueno, H (2016) Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis

More information

Timing of Surgery After Percutaneous Coronary Intervention

Timing of Surgery After Percutaneous Coronary Intervention Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet

More information

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of

More information

NEBRASKA STEMI CONFERENCE 2015 Dr. Doug Kosmicki. 2013, American Heart Association

NEBRASKA STEMI CONFERENCE 2015 Dr. Doug Kosmicki. 2013, American Heart Association NEBRASKA STEMI CONFERENCE 2015 Dr. Doug Kosmicki 2013, American Heart Association 1 Dr. Doug Kosmicki Reperfusion Strategies Disclosure Information Report any disclosure information of conflicts of interest.

More information

Bivalirudin should be indicated for all patients with STEMI. Adnan Kastrati Deutsches Herzzentrum, Munich, Germany

Bivalirudin should be indicated for all patients with STEMI. Adnan Kastrati Deutsches Herzzentrum, Munich, Germany Bivalirudin should be indicated for all patients with STEMI Adnan Kastrati Deutsches Herzzentrum, Munich, Germany 1 Heparin+IIb/IIIa, heparin alone or bivalirudin in STEMI: Do we have the answer? 2 Heparin+IIb/IIIa,

More information

The PAIN Pathway for the Management of Acute Coronary Syndrome

The PAIN Pathway for the Management of Acute Coronary Syndrome 2 The PAIN Pathway for the Management of Acute Coronary Syndrome Eyal Herzog, Emad Aziz, and Mun K. Hong Acute coronary syndrome (ACS) subsumes a spectrum of clinical entities, ranging from unstable angina

More information

Guideline for STEMI. Reperfusion at a PCI-Capable Hospital

Guideline for STEMI. Reperfusion at a PCI-Capable Hospital MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure

More information

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic

More information

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

Chronic kidney disease (CKD) is frequently encountered

Chronic kidney disease (CKD) is frequently encountered AHA Scientific Statement Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome A Scientific Statement From the American Heart Association Jeffrey B. Washam, PharmD,

More information

When the learner has completed this module, she/he will be able to:

When the learner has completed this module, she/he will be able to: Thrombolytics and Myocardial Infarction WWW.RN.ORG Reviewed September 2017, Expires September 2019 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2017

More information

Quinn Capers, IV, MD

Quinn Capers, IV, MD Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular

More information

Critical Review Form Therapy Objectives: Methods:

Critical Review Form Therapy Objectives: Methods: Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To

More information

Citation for published version (APA): Mahmoud, K. (2014). Symptom onset and treatment in acute myocardial infarction. [S.l.]: [S.n.].

Citation for published version (APA): Mahmoud, K. (2014). Symptom onset and treatment in acute myocardial infarction. [S.l.]: [S.n.]. University of Groningen Symptom onset and treatment in acute myocardial infarction Mahmoud, Karim IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite

More information

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol

More information

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply. WHI Form - Report of Cardiovascular Outcome Ver. 6. COMMENTS To be completed by Physician Adjudicator Date Completed: - - (M/D/Y) Adjudicator Code: OMB# 095-044 Exp: 4/06 -Affix label here- Clinical Center/ID:

More information

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy

More information

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual

More information

Objectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?

Objectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start? Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Controversies in Cardiac Pharmacology

Controversies in Cardiac Pharmacology Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?

More information

DISCUSSION QUESTION - 1

DISCUSSION QUESTION - 1 CASE PRESENTATION 87 year old male No past history of diabetes, HTN, dyslipidemia or smoking Very active Medications: omeprazole for heart burn Admitted because of increasing retrosternal chest pressure

More information

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,

More information

Acute Coronary Syndrome. Sonny Achtchi, DO

Acute Coronary Syndrome. Sonny Achtchi, DO Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification

More information